Business

Novartis malaria treatment Coartem® Baby receives WHO prequalification April 26, 2026 | Sunday | News Coartem® (artemether-lumefantrine) Baby…

Investors have become more encouraged that a durable end to the US-Israel-Iran war is in sight. News of…

This panel brings together leading voices to reflect on the seismic shifts that have shaped the art market…

The use of indices is for illustrative purposes only. Unlike the Fund, some indices are unmanaged, are not…

US equities hit new record highs on Wednesday as a strong start to the first-quarter earnings season eased…

The reopening of the Strait of Hormuz remains elusive despite the ceasefire. While the White House suggests it…

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…

Novartis received a positive opinion from the European Medicines Agency for its gene therapy Itvisma for spinal muscular…

We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 22 April 2026,…

Identifying trends before they become apparent The limitations of data-driven models become particularly apparent when it comes to…

is getting booked ahead of supply. That’s why it forecasts AWS revenue rising 38% in 2026, above analysts’…

Please create an employee account to be able to mark statistics as favorites. Then you can access your…

Novartis malaria treatment Coartem® Baby receives WHO prequalification